Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Cannabics Pharmaceuticals Inc. | cannabics_ex9901.htm |
| EX-10.1 - SERVICE AGREEMENT - Cannabics Pharmaceuticals Inc. | cannabics_ex1001.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 16th, 2020
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-192759 | 20-3373669 |
| (State of incorporation) | (Commission File Number) | (IRS Employer No.) |
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices and Zip Code)
877 424-2429
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 7.01 REGULATION FD DISCLOSURE
The Company has established a subsidiary named Digestix Bioscience Inc. This new subsidiary is specifically dedicated to the development of medical devices and pharmaceutical compositions for the treatment of precancerous and early stage neoplastic local tumors. The new company’s initial focus is in developing a device and a pharmaceutical composition with inhibitory effects for preventing recurrence of certain adenomatous colorectal polyps.
Gabriel Yariv, Company Director and COO, was also chosen to assume the role of interim chairman and CEO for Digestix Bioscience Inc. during this initial phase. Additionally, there is a Service Agreement, by which the Company shall be paid a service fee by Digestix of Cost +15%.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS,
(d) Exhibits.
| Exhibit | |
| Number | Description |
| 10.1 | Service Agreement |
| 99.1 | Press Release re Digestix |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: November 16th, 2020 | CANNABICS PHARMACEUTICALS, INC. | |
| By: | /s/ Eyal Barad | |
| Name: | Eyal Barad | |
| Title: | Chief Executive Officer | |